Perrigo has said it is evaluating strategic alternatives for the rights to the royalty stream from sales of the multiple sclerosis drug, Tysabri (natalizumab), as part of its ongoing business portfolio review. Tysabri is a US Food and Drug Administration-approved treatment for multiple sclerosis. Perrigo acquired the rights to the Tysabri royalty stream through its 2013 acquisition of Elan Corporation.

Perrigo has engaged Morgan Stanley as its financial advisor to lead the review of strategic alternatives process for Tysabri. The company has said that there can be no assurances that this strategic review will result in a transaction.

Source: Perrigo